Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics, Inc. (VVOS) scores 51 out of 100 on boothcheck's 11-model valuation framework. Verdict: Poor The estimated fair value is 2.41, representing a 108% margin of safety. Quantitative score: 49/100. Qualitative score: 80/100.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full VVOS analysis on boothcheck